Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

Nat Rev Microbiol. 2007 Jul;5(7):540-53. doi: 10.1038/nrmicro1662.

Abstract

More than 50 years of research has yielded numerous Shigella vaccine candidates that have exemplified both the promise of vaccine-induced prevention of shigellosis and the impediments to developing a safe and effective vaccine for widespread use, a goal that has yet to be attained. This Review discusses the most advanced strategies for Shigella vaccine development, the immune responses that are elicited following disease or vaccination, the factors that have accelerated or impeded Shigella vaccine development and our ideas for the way forward.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Bacterial / blood
  • Child, Preschool
  • Clinical Trials as Topic*
  • Dysentery, Bacillary / epidemiology
  • Dysentery, Bacillary / immunology
  • Dysentery, Bacillary / microbiology
  • Dysentery, Bacillary / prevention & control*
  • Humans
  • Immunity, Cellular
  • Infant
  • Shigella / classification*
  • Shigella / immunology*
  • Shigella Vaccines* / administration & dosage
  • Shigella Vaccines* / adverse effects
  • Shigella Vaccines* / immunology
  • Vaccination
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology

Substances

  • Antibodies, Bacterial
  • Shigella Vaccines
  • Vaccines, Attenuated